References
- Brugiatelli M, Bandini G, Barosi G, Lauria F, Liso V, Marchetti M, et al. Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006; 91: 1662–1673
- Chiorazzi N, Ferrarini M. Evolving view of the in vivo kinetics of chronic lymphocytic leukemia B cells. Hematology Am Soc Hematol Educ Program 2006; 512: 273–278
- Everett P C, Meyers J A, Makkinje A, Rabbi M, Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol 2007; 82: 23–30
- Jagetia G C, Aggarwal B B. “Spicing up” of the immune system by curcumin. J Clin Immunol 2007; 27: 19–35
- Ramalingam S, Belani C P. Recent advances in targeted therapy for non-small cell lung cancer. Expert Opin Ther Targets 2007; 11: 245–257
- Singh S, Khar A. Biological effects of curcumin and its role in cancer chemoprevention and therapy. Anticancer Agents Med Chem 2006; 6: 259–270
- Swat W, Ignatowicz L, Kisielow P. Detection of apoptosis of immature CD4+8+thymocytes by flow cytometry. J Immunol Methods 1991; 137: 79–87
- Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F, et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003; 101: 278–285
- Faried L S, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, et al. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 2006; 42: 934–947
- Bokelmann I, Mahlknecht U. Valproic acid sensitises chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 2008; 14: 20–27
- Garcia J A, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. Mol Cancer Ther 2008; 7: 1347–1354
- Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19: 1387–1392
- Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Ann Hematol 2009; 88: 221–227
- Binion D G, Otterson M F, Rafiee P. Curcumin inhibits VEGF mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK Inhibition. Gut 2008; 57: 1509–1517
- Sun C Y, Liu X Y, Chen Y, Liu F, Wang Y. Experimental study on anticancer effect of curcumin on Raji cells in vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004; 24: 1003–1006
- Gotze K S, Hoffmann D, Schatzl H M, Peschel C, Fend F, Decker T. Fatal Epstein-Barr virus-associated lymphoproliferative disorder following treatment with a novel mTOR inhibitor for relapsed chronic lymphocytic leukemia leukemia cells. Haematologica 2007; 92: 1282–1283
- Ringshausen I, Peschel C, Decker T. Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leuk Lymphoma 2005; 46: 11–19